Clinical Trial Update: Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating imatinib mesylate in combination with interferon alfa for chronic myeloid leukemia was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2012-08-20